Revvity

RVTY · NYSE

$156.01+$5.07 (+3.36%)TodayMarket closed ·
Prev close $150.94

About RVTY

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company is headquartered in Waltham, Massachusetts and currently employs 11,000 full-time employees. The firm has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.

Employees
11,000
Headquarters
Waltham, Massachusetts
Listed
Jul 6, 1965
Sector
Health Care
Industry
Life Sciences Tools & Services

Leadership

Revvity executives
NameTitleSince
Alexandros Michas——
Prahlad Singh—2016
Maxwell Krakowiak——
Joel Goldberg——
Miriame Victor——
Tajinder Vohra——
Anita Gonzales——
Peter Barrett——
Samuel Chapin——
Michael Klobuchar——
Michelle Mcmurry-Heath——
Sophie Vandebroek——
Michel Vounatsos——
Frank Witney——
Pascale Witz——

Similar companies

Companies in the same industry as Revvity

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.